FASN and glioblastoma: In all four pairs, newly diagnosed GBM showed a significant reduction or a trend towards it in mRNA levels of FASN, FADS2 and SCD (Figures 3B-D and Supplementary Figure S3) upon TMZ treatment, while recurring GBMs showed either no significant effect or even an increase in the mRNA expression.